Belluscura PLC (GB:BELL) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Belluscura PLC has announced a joint venture with Separation Design Group and a major medical device company to develop oxygen-based wound care solutions, focusing on continuously diffused oxygen therapy. This collaboration positions Belluscura to capitalize on the growing $22.5 billion wound care market by leveraging its expertise in oxygen technology and the partner’s distribution capabilities. The initial clinical study is set to begin in early 2025 outside the U.S., marking a significant step in addressing hard-to-heal wounds.
For further insights into GB:BELL stock, check out TipRanks’ Stock Analysis page.